Shirin Khambata‐Ford
About
Shirin Khambata‐Ford is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Shirin Khambata‐Ford has authored 34 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Shirin Khambata‐Ford's work include Colorectal Cancer Treatments and Studies (23 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Treatment and Pharmacology (7 papers). Shirin Khambata‐Ford is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Treatment and Pharmacology (7 papers). Shirin Khambata‐Ford collaborates with scholars based in United States, Canada and Australia. Shirin Khambata‐Ford's co-authors include Christos S. Karapetis, Derek J. Jonker, John Zalcberg, Chris J. O’Callaghan, Dongsheng Tu, Malcolm J. Moore, R. J. Simes, Niall C. Tebbutt, Christiane Langer and Timothy Price and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.
In The Last Decade
Shirin Khambata‐Ford
34 papers receiving 5.3k citations
Hit Papers
Peers
Shirin Khambata‐Ford
Christiane Langer United States
Sabine Tejpar Belgium
Angela Zubel Germany
Kelly S. Oliner United States
Claus-Henning Köhne Germany
Michael Schlichting Germany
Dominik Paul Modest Germany
Arnaud Roth Switzerland
Allen Lee Cohn United States
Christopher R. Garrett United States
Citations per year, relative to Shirin Khambata‐Ford Shirin Khambata‐Ford (= 1×)
peers
Christiane Langer
Countries citing papers authored by Shirin Khambata‐Ford
Since
Specialization
Citations
This map shows the geographic impact of Shirin Khambata‐Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shirin Khambata‐Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shirin Khambata‐Ford more than expected).
Fields of papers citing papers by Shirin Khambata‐Ford
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shirin Khambata‐Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shirin Khambata‐Ford. The network helps show where Shirin Khambata‐Ford may publish in the future.
Co-authorship network of co-authors of Shirin Khambata‐Ford
This figure shows the co-authorship network connecting the top 25 collaborators of Shirin Khambata‐Ford. A scholar is included among the top collaborators of Shirin Khambata‐Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shirin Khambata‐Ford. Shirin Khambata‐Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Qi, Zhenhao, Shinya Tokuhiro, Justin I. Odegaard, et al.. (2025). Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02. Journal of Molecular Diagnostics. 27(2). 119–129.
2.
Chang, Ken C. N., Maha Karnoub, Li Liu, et al.. (2023). Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD) Companion Diagnostic Development. Blood. 142(Supplement 1). 4260–4260.
3.
Dietel, Manfred, Н. А. Савелов, Patrick Micke, et al.. (2019). Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer. 134. 174–179.
4.
Dietel, Manfred, Н. А. Савелов, Patrick Micke, et al.. (2018). 130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study. Journal of Thoracic Oncology. 13(4). S74–S75.
5.
Ilié, Marius, Jonathan Juco, Lingkang Huang, et al.. (2018). Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients. Cancer Cytopathology. 126(4). 264–274.
6.
Ilié, Marius, Shirin Khambata‐Ford, Christiane Copie‐Bergman, et al.. (2017). Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE. 12(8). e0183023–e0183023.
7.
Denne, Jonathan, Luping Zhao, Christine E. Horak, et al.. (2013). Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay. Clinical Colorectal Cancer. 12(3). 195–203.e2.
8.
Jonker, Derek J., Christos S. Karapetis, Christopher Harbison, et al.. (2013). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer. 110(3). 648–655.
9.
Huang, Fei, Lian Xu, & Shirin Khambata‐Ford. (2012). Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer. Clinical Cancer Research. 18(4). 1156–1166.
10.
Baker, Joffre, Debjani Dutta, Drew Watson, et al.. (2011). Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. British Journal of Cancer. 104(3). 488–495.
11.
Lynch, Timothy, et al.. (2011). 9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane. European Journal of Cancer. 47. S591–S592.
12.
Roock, Wendy De, Derek J. Jonker, Federica Di Nicolantonio, et al.. (2010). Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA. 304(16). 1812–1812.
13.
Huang, Fei, Lian Xu, & Shirin Khambata‐Ford. (2010). Abstract 2697: Analysis of the correlation between gene expression of IGF-pathway components and benefit from cetuximab (Erbitux™) in metastatic colorectal cancer patients. Cancer Research. 70(8_Supplement). 2697–2697.
14.
Khambata‐Ford, Shirin, Christopher Harbison, Donald Woytowitz, et al.. (2009). K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial. Journal of Clinical Oncology. 27(15_suppl). 8021–8021.
15.
Winder, Thomas, W. Zhang, Anthony B. El-Khoueiry, et al.. (2009). Association of a germ-line variant in the K-ras 3’ untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. Journal of Clinical Oncology. 27(15_suppl). 4061–4061.
16.
Carey, Lisa A., Joyce O’Shaughnessy, Shirin Khambata‐Ford, et al.. (2009). Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.. Cancer Research. 69(24_Supplement). 2014–2014.
17.
Karapetis, Christos S., Shirin Khambata‐Ford, Derek J. Jonker, et al.. (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine. 359(17). 1757–1765.
18.
Maddala, Tara, S. Shak, Eric K. Rowinsky, et al.. (2008). Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology. 26(15_suppl). 3512–3512.
19.
Khambata‐Ford, Shirin, Christopher R. Garrett, Neal J. Meropol, et al.. (2007). Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. Journal of Clinical Oncology. 25(22). 3230–3237.
20.
Khambata‐Ford, Shirin, Yueyi Liu, Mark Dickson, et al.. (2003). Identification of Promoter Regions in the Human Genome by Using a Retroviral Plasmid Library-Based Functional Reporter Gene Assay. Genome Research. 13(7). 1765–1774.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christiane Langer Breakdown of academic impact, for papers by Sabine Tejpar Breakdown of academic impact, for papers by Angela Zubel Breakdown of academic impact, for papers by Kelly S. Oliner Breakdown of academic impact, for papers by Claus-Henning Köhne Breakdown of academic impact, for papers by Michael Schlichting Breakdown of academic impact, for papers by Dominik Paul Modest Breakdown of academic impact, for papers by Arnaud Roth Breakdown of academic impact, for papers by Allen Lee Cohn Breakdown of academic impact, for papers by Christopher R. Garrett